Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26772294 | 0.89 | IL1B (0.78) | IL1BNLRP3 | |
| SCHEMBL27110757 | 0.88 | IL1B (0.86) | IL1BNLRP3 | |
| SCHEMBL22654980 | 0.88 | IL1B (1.00) | IL1BNLRP3 | |
| SCHEMBL22654806 | 0.88 | IL1B (1.00) | IL1BNLRP3 | |
| SCHEMBL22654809 | 0.88 | IL1B (1.00) | IL1BNLRP3 | |
| SCHEMBL29508531 | 0.88 | IL1B (1.00) | IL1BNLRP3 | |
| SCHEMBL29508564 | 0.88 | IL1B (1.00) | IL1BNLRP3 | |
| SCHEMBL29508540 | 0.88 | IL1B (1.00) | IL1BNLRP3 | |
| SCHEMBL26772273 | 0.86 | IL1B (0.70) | IL1BNLRP3 | |
| SCHEMBL26772263 | 0.86 | IL1B (0.76) | IL1BNLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067627-A1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS AG (CH) | 2024-02-29 | — | — | US | disclosed |
| US-11254653-B2 | NLRP3 inflammasome inhibitors | NOVARTIS AG (CH) | 2022-02-22 | — | — | US | disclosed |
| US-20200361899-A1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS PHARMA AG (CH) | 2020-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254653-B2 | NLRP3 inflammasome inhibitors | NLRP3, NLRP1, NOD1 | IL1B 11/4885NLRP3 1/4885 |
| US-20240067627-A1 | NLRP3 INFLAMMASOME INHIBITORS | NLRP3, NLRP1, NOD1 | IL1B 11/4885NLRP3 1/4885 |
| US-20200361899-A1 | NLRP3 INFLAMMASOME INHIBITORS | NLRP3, NLRP1, NOD1 | IL1B 11/4885NLRP3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.